跳至主要内容
临床试验/NCT01121315
NCT01121315已完成不适用

A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Glucose Lowering Drug Treatment in Primary Care

AstraZeneca1 个研究点 分布在 1 个国家目标入组 58,326 人开始时间: 2010年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
58,326
试验地点
1
主要终点
Composite end-point consisting of Cardiovascular Disease, elective coronary revascularisation and mortality

研究概览

简要总结

To describe the type II diabetes population in primary care with special reference to treatment, other diseases and mortality during the last decade. To test the hypothesis that the type or combination of per oral glucose lowering drugs have different effects on the risk of cardiovascular disease and diabetic complications.

研究设计

研究类型
Observational
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with type II diabetes, according to medical records, diagnosis, prescription or lab assessments

排除标准

  • Patients followed by physician for less than 6 months after diagnosis of Diabetes type II

结局指标

主要结局

Composite end-point consisting of Cardiovascular Disease, elective coronary revascularisation and mortality

时间窗: The endpoints will be extracted from the medical records on one occassion, covering a period of one decade.

次要结局

  • Retinopathy, renal failure, hypoglycaemic episodes, other diabetic complications(The endpoints will be extracted from the medical records on one occasion, covering a period of one decade.)
  • Time from: Metformin (MET) to Insulin (INS) versus Metformin (MET) -> Metformin (MET)+Sulfonylurea (SU) ->Insulin (INS)(The endpoints will be extracted from the medical records on one occasion, covering a period of one decade.)
  • Number of consultations in primary care. Number of hospitalisations(The endpoints will be extracted from the medical records on one occasion, covering a period of one decade.)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验